Glaucoma Pharmaceutical Market

Glaucoma Pharmaceutical Market: Overview

Glaucoma is one of the key causes of blindness, and millions of people suffer with visual impairment from glaucoma with a high incidence in those older than 65 years. The condition further accounts for 12% of all cases of preventable blindness. According to an estimate of National Eye Institute, 4 million Americans will have glaucoma. As large proportion of population in emerging economies enter that cohort, there is a pressing need for better understanding of pharmacology of the disease, causing the glaucoma pharmaceutical market to evolve.

Focus on intraocular pressure (IOP)-lowering medical interventions has made strides in the glaucoma pharmaceutical market. Advances in pharmacological treatments and ocular surgery procedures have bolstered new prospects in the glaucoma pharmaceutical market.

The study presents a detailed assessment of key avenues, major clinical developments, new directions of research and development, and share and size of various segments, and insights into prominent regional glaucoma pharmaceutical markets.

Glaucoma Pharmaceutical Market: Key Trends

Advances in the understanding of the pharmacology have shaped the research directions in the glaucoma pharmaceutical market. Until the past few years, players in the glaucoma pharmaceutical market were interested in neuroprotective agents. Nevertheless, over time, their popularity has declined, due to difficulty in assessing their efficacy.

In recent years, the clinical studies boosting new avenues in the glaucoma pharmaceutical market have swayed toward efforts in identifying valuable functional endpoints. This has also focused on finding new and better anatomical targets for neuroprotective drugs, apart from retinal ganglion cell (RGC).

Glaucoma Pharmaceutical Market: Key Developments

Geographically, North America and Europe are promising markets. These are driven by the growing awareness about the morbidity and mortality of the disease in the regional population. Asia Pacific is expected to attract new swathes of investments. The prospects have been bolstered in recent years by growing body of clinical studies in the region.